Every 8-K that Inhibikase Therapeutics Inc (IKT) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow IKT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full IKT filings page.
Inhibikase Therapeutics, Inc. (IKT) furnished an updated corporate overview describing its lead candidate IKT-001, a novel oral prodrug of imatinib in a pivotal Phase 3 program for pulmonary arterial hypertension (PAH), a rare disease with about 30% 5‑year mortality and a $8.3 billion global market in 2025.
The company highlights that imatinib previously showed antiproliferative efficacy in PAH, including a placebo‑adjusted 45‑meter improvement in 6‑minute walk distance and a 32% reduction in pulmonary vascular resistance, but was limited by tolerability. IKT-001 is designed to retain efficacy while improving gastrointestinal tolerability and is being studied in the IMPROVE‑PAH Phase 3 trial with a 12‑week dose‑titration design across 26 countries and 46 of a planned ~180 sites active. The program has Orphan Drug Designation, is being advanced under a 505(b)(2) regulatory pathway, and the company indicates expected cash runway through the Phase 3 Part B topline readout, assuming full and timely exercise of outstanding Series A and B warrants.
Inhibikase Therapeutics, Inc. (IKT) reported that its Audit Committee dismissed CohnReznick LLP as independent registered public accounting firm on August 21, 2026, and, effective immediately thereafter, appointed Deloitte & Touche LLP as the new independent registered public accounting firm for the fiscal year ending December 31, 2026. CohnReznick’s audit reports for the years ended December 31, 2025 and 2024 contained no adverse opinions, disclaimers, or qualifications, and the company states there were no disagreements on accounting principles, financial disclosure, or audit scope. CohnReznick had previously advised that a material weakness in internal control over financial reporting existed during the year ended December 31, 2024; this was earlier disclosed and described as remediated by prior management by the quarter ended September 30, 2024. Other than that reportable event, the company reports no additional reportable events during 2025, 2024, or subsequent interim periods.
Inhibikase Therapeutics reported second quarter 2026 results and clinical progress for its lead PAH candidate IKT-001. The company highlighted continued advancement of its single pivotal Phase 3 IMPROVE-PAH trial, with 26 country regulatory approvals and 43 clinical sites recently initiated. IKT-001 has shown favorable preclinical and Phase 1 data and received Orphan Drug Designation from the U.S. FDA.
As of June 30, 2026, cash, cash equivalents and marketable securities totaled $159.0 million. After quarter-end, Inhibikase sold 25,000,000 common shares to RA Capital Management through its ATM facility for $50 million in gross proceeds, and expects its capital resources to fund operations through topline Part B data from IMPROVE-PAH, assuming full and timely exercise of Series A and B warrants. For the quarter, net loss was $19.6 million, or $0.11 per share, compared with $9.9 million, or $0.11 per share a year earlier, driven by higher research and development expenses of $13.4 million and selling, general and administrative expenses of $7.7 million.
Inhibikase Therapeutics, Inc. entered into an exchange agreement with RA Capital Healthcare Fund, L.P. on July 29, 2026. RA Capital exchanged 18,030,000 shares of common stock for a pre-funded warrant to acquire 18,030,000 shares of common stock.
The pre-funded warrant has a $0.001 exercise price per share, is immediately exercisable, has no expiration date, and is adjustable for stock splits and similar events. A beneficial ownership blocker generally limits RA Capital’s ownership upon exercise to 9.99% of outstanding common stock, adjustable with 61 days’ notice up to 19.99%. The warrant was issued in an unregistered exchange relying on Section 3(a)(9) of the Securities Act of 1933.
Inhibikase Therapeutics, Inc. reports that the FDA’s Office of Orphan Products Development has granted Orphan Drug Designation to its lead candidate IKT-001, a prodrug of imatinib mesylate, for the treatment of Pulmonary Arterial Hypertension (PAH), a rare, progressive cardiopulmonary disease affecting approximately 50,000 people in the United States.
The company cites preclinical data showing improvements in pulmonary vascular and hemodynamic markers of PAH and a lower potential for GI toxicity compared with imatinib mesylate. Orphan status can provide incentives including tax credits on qualified clinical trial costs, exemption from certain FDA user fees, and the potential for seven years of U.S. market exclusivity upon regulatory approval. IKT-001 is being evaluated in IMPROVE-PAH, a single pivotal Phase 3 study at approximately 180 sites worldwide that is actively enrolling patients.
Inhibikase Therapeutics, Inc. disclosed that it sold 25,000,000 shares of common stock to RA Capital Management through its at-the-market facility, generating gross proceeds of $50 million under an existing shelf registration statement on Form S-3 and related ATM prospectus supplement.
The company expects this additional capital, together with existing cash reserves, to support operations through topline data readout in Part B of its ongoing global Phase 3 IMPROVE-PAH trial of IKT-001 for Pulmonary Arterial Hypertension, subject to the full exercise of outstanding Series A and B Warrants.
Inhibikase is a clinical-stage pharmaceutical company developing IKT-001, a prodrug of imatinib, for Pulmonary Arterial Hypertension, a progressive, life-threatening disease that affects approximately 50,000 Americans, with its single pivotal Phase 3 IMPROVE-PAH study actively enrolling at about 180 sites worldwide.
Inhibikase Therapeutics, Inc. held its 2026 annual meeting of stockholders in a virtual format, where all six management proposals were approved. Stockholders backed an amendment to the 2020 Equity Incentive Plan, increasing the shares reserved for issuance by 3,000,000 common shares.
They also approved a Certificate of Amendment to limit the liability of certain officers as permitted by Delaware law, ratified CohnReznick LLP as independent auditor for 2026, and supported executive compensation on an advisory basis. Directors Arvind Kush and Dennis Berman were re‑elected as Class III directors, and investors chose to hold future say‑on‑pay votes annually.
Inhibikase Therapeutics reported first quarter 2026 results and progress on its Pulmonary Arterial Hypertension program. The company enrolled the first patient in its registrational IMPROVE-PAH Phase 3 study and has obtained regulatory approvals in 16 countries, helped by the EMA’s new FAST-EU initiative.
As of March 31, 2026, cash, cash equivalents and marketable securities were $170.4 million. Net loss was $16.4 million, or $0.10 per share, compared with a net loss of $13.7 million, or $0.15 per share, a year earlier. Research and development expenses were $10.8 million, while selling, general and administrative costs were $7.4 million, both up versus the prior-year quarter.
Inhibikase Therapeutics filed an 8-K to share news that the first patient has been enrolled in its pivotal global Phase 3 IMPROVE-PAH study of IKT-001 for Pulmonary Arterial Hypertension (PAH). This marks a key step in moving the program into late-stage testing.
IKT-001 is a novel oral prodrug of imatinib mesylate, designed to lessen gastrointestinal side effects associated with imatinib. The IMPROVE-PAH trial uses a two-part adaptive Phase 3 design with a 12-week dose‑titration phase to help patients reach the highest tolerable dose.
Part A will enroll approximately 140 patients and measure change in pulmonary vascular resistance at Week 24. Part B will follow seamlessly, enrolling about 346 patients and focusing on change in 6-minute walk distance at Week 24. The study may include up to roughly 180 sites worldwide and allows for sample size re-estimation for Part B based on Part A findings. Inhibikase describes PAH as a progressive, life‑threatening disease affecting about 50,000 Americans and views this single pivotal Phase 3 trial as central to advancing IKT-001 toward potential regulatory review.
Inhibikase Therapeutics reported a larger net loss for 2025 as it advanced its lead Pulmonary Arterial Hypertension program into a global pivotal Phase 3 trial called IMPROVE-PAH. Net loss was $48.3 million, or $0.49 per share, compared with $27.5 million, or $1.16 per share in 2024.
Research and development expenses rose to $29.8 million, including a $7.4 million non-cash write-off of in-process R&D and $2.5 million of stock-based compensation tied to the February 2025 CorHepta acquisition. Selling, general and administrative expenses increased to $23.6 million, including $1.0 million of severance from senior executive transitions.
Cash, cash equivalents and marketable securities were $178.8 million as of December 31, 2025, up from $97.5 million a year earlier, supported by $107.6 million of net proceeds from issuing common stock, pre-funded warrants and warrants. The company highlighted ongoing regulatory submissions in more than 20 countries and active enrollment in its single pivotal Phase 3 PAH study.
Inhibikase Therapeutics announced an underwritten public offering of 46,091,739 shares of common stock and pre-funded warrants to purchase up to 22,873,779 additional shares. Each share is priced at $1.45 and each pre-funded warrant at $1.449, with an exercise price of $0.001 per share. The company granted underwriters a 30-day option to buy up to 10,344,827 more shares at the public offering price, less underwriting discounts and commissions.
Inhibikase expects net proceeds of approximately $93.6 million, or $107.7 million if the underwriters’ option is fully exercised. The pre-funded warrants are immediately exercisable and include ownership caps generally at 4.99% or 9.99%, adjustable up to 19.99% with notice. The company also amended outstanding Series A-1 and Series B-1 warrants issued in 2024 to reflect its plan to advance IKT-001 to a global pivotal Phase 3 trial in pulmonary arterial hypertension.
Inhibikase Therapeutics plans to advance its drug candidate IKT-001 directly into a global pivotal Phase 3 trial for pulmonary arterial hypertension (PAH). The Phase 3 IMPROVE-PAH study is expected to start in the first quarter of 2026 and use a two-part adaptive design. Part A will be a double-blind, placebo-controlled study in 140 patients with a primary endpoint of pulmonary vascular resistance at Week 24, while Part B will use the same format in 346 patients with a primary endpoint of six-minute walk distance at Week 24. The company believes this design offers advantages such as dose titration to the highest tolerable dose, uninterrupted enrollment, and potential sample size re-estimation. Inhibikase also terminated its at-the-market sales agreement prospectus with Jefferies, having made no stock sales under it, although the underlying sales agreement remains in effect.
Inhibikase Therapeutics, Inc. filed a current report noting that it has announced its financial results for the quarter ended June 30, 2025 and provided other corporate updates through a press release. The press release is furnished as an exhibit and is not treated as part of the company’s formal, liability-bearing SEC filings unless later specifically incorporated by reference.
The company also updated its corporate presentation for use in meetings with investors, analysts and others, and furnished this presentation as a separate exhibit. Both the press release and the presentation are being shared for informational purposes under the Exchange Act without being deemed formally filed.